Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. (FRX.TO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
frx.to · stock forecast · 7 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $12.72
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $13.25 | ↑ 4.20% |
1-day model range: $13.07–$13.44. Peak: $13.44 (+4.20%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $12 | -9.0% |
| 2028 | $11 | -13.6% |
| 2029 | $11 | -15.9% |
| 2030 | $11 | -17.2% |
| 2031 | — | -17.9% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · FRX.TO · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-22 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-04-16 | Wedbush | Maintains | Outperform→Outperform |
| 2025-08-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-15 | Craig-Hallum | Maintains | Buy→Buy |
| 2025-05-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-14 | Craig-Hallum | Maintains | Buy→Buy |
| 2025-03-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-22 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-14 | Craig-Hallum | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Fennec Pharmaceuticals Inc. (FRX.TO) stock. Of the recent 32 rating actions, 1 were upgrades and 0 were downgrades. 7 analysts currently cover FRX.TO.
Analyst Recommendation Trends
FRX.TO analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$68M
↓ 51.1% YoY
Revenue Next Year
$102M
↑ 49.8% YoY
EPS This Year
$0.26
EPS Next Year
$1.01
↑ 284.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast FRX.TO EPS of $0.26 for the current fiscal year, based on estimates from 6 analysts. The FRX.TO revenue forecast is $68M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The FRX.TO stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus FRX.TO price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The FRX.TO short-term stock prediction for tomorrow is $13.25 (+4.20%). The FRX.TO stock price prediction for 2027 estimates an average of $12. The FRX.TO stock prediction for 2030 projects a range of $9–$12.
Fennec Pharmaceuticals Inc. trades on TSX under the ticker FRX.TO. The FRX.TO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
FRX.TO forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month FRX.TO price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $12.72.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.